Novo Nordisk to acquire cardio-renal disease company Corvidia Therapeutics
Novo Nordisk acquisition of Corvidia : Danish pharma company Novo Nordisk has agreed to acquire Corvidia Therapeutics from life sciences venture capital firm Sofinnova Partners in a deal worth up to $2.1 billion, in a move to expand its presence in cardiovascular disease. Corvidia Therapeutics, which is based in Boston, Massachusetts, was spun out from […]